With all of the pipeline success we're seeing from the Big Biotech stocks lately, Big Pharma's more hit-and-miss recent drug development track record hasn't gone unnoticed.
Today, Pfizer announced that it was halting a phase 3 trial for inotuzumab ozogamicin in aggressive non-Hodgkin's lymphoma, as it wasn't showing any survival benefit over the control group. It was a surprise cancellation, and there had been a lot of enthusiasm around this drug, which targeted an antigen found in more than 90% of b-cell malignancies.
In this video, health-care analyst David Williamson discusses what this drug failure means for Pfizer, its competitors, and its investors.
Another topic health-care investors need to keep up on is Obamacare, as the law will undoubtedly have far-reaching effects. The Motley Fool's new free report "Everything You Need to Know About Obamacare," lets you know how your health insurance, your taxes, and your portfolio will be affected. Click here to read more.